Table 1 Baseline characteristics of the analytical sample
Selected Predictors | Placebo (n = 320) | 75 mg Mepolizumab (n = 314) | p-value |
|---|---|---|---|
Age (years), mean (SD) | 47.6 (13.3) | 49.8 (13.1) | 0.027 |
Female, n (%) | 191 (59.7) | 192 (61.1) | 0.71 |
Ethnicity (Hispanic or Latino), n (%) | 31 (9.7) | 32 (10.2) | 0.83 |
Smokers, n (%) | 67 (20.9) | 74 (23.6) | 0.43 |
Body Mass Index (kg/m 2 ), mean (SD) | 28.2 (5.9) | 27.9 (5.8) | 0.80 |
Duration of asthma (years), mean (SD) | 18.8 (14.3) | 19.1 (13.8) | 0.55 |
Nasal polyps, n (%) | 45 (14.1) | 40 (12.7) | 0.62 |
Percentage of predicted pre-bronchodilator FEV1, mean (SD) | 61.0 (17.0) | 60.3 (17.5) | 0.75 |
FEV 1 Reversibility (%), mean (SD) | 26.8 (22.4) | 26.3 (20.3) | 0.92 |
Post-bronchodilator FEV 1 /FVC, mean (SD) | 0.65 (0.13) | 0.66 (0.13) | 0.43 |
ACQ5 score, mean (SD) | 2.33 (1.12) | 2.17 (1.10) | 0.10 |
Blood eosinophil count (×10 9 /L), mean (SD) | 0.44 (0.39) | 0.41 (0.38) | 0.16 |
Serum IgE (U/ml), mean (SD) | 434.3 (853.4) | 552.0 (1323.7) | 0.50 |
Maintenance daily dose of oral corticosteroid, n (%) | 79 (24.7) | 79 (25.2) | 0.89 |
No. of severe exacerbations in the previous year, mean (SD) | 3.6 (3.4) | 3.6 (2.7) | 0.64 |
No. of exacerbations requiring hospitalization in previous year, mean (SD) | 0.6 (1.5) | 0.5 (1.0) | 0.75 |